{"denoms":[{"counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"49"}],"units":"Participants"}],"groups":[{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.\n\nGlutamine: Administered orally twice daily for 21 days","id":"BG000","title":"Arm I: Glutamine"},{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.\n\nPlacebo: Administered orally twice daily for 21 days","id":"BG001","title":"Arm II: Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"5","upperLimit":"19","value":"11"},{"groupId":"BG001","lowerLimit":"4","upperLimit":"17","value":"10"},{"groupId":"BG002","lowerLimit":"4","upperLimit":"19","value":"11"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"23"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"49"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Fifty-six patients were enrolled and 49 were evaluable."}